
CLAIMS

1. A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,



(III)

wherein

T_1 is selected from O and N;

R_1 is selected from C_{6-10} aryl and 5- to 10-membered heteroaryl, wherein the C_{6-10} aryl and 5- to 10-membered heteroaryl are optionally substituted with 1, 2, 3, 4 or 5 R_a;

when T_1 is O, R_2 is not present;

when T_1 is N, R_2 is selected from H, C_{1-3} alkyl, -C(=O)-C_{1-3} alkyl and -S(=O)$_2$-C_{1-3} alkyl, wherein the C_{1-3} alkyl, -C(=O)-C_{1-3} alkyl and -S(=O)$_2$-C_{1-3} alkyl are optionally substituted with 1, 2 or 3 R_b;

R_3 is C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_c;

R_4 is selected from H and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_d;

R_5, R_6 and R_7 are each independently selected from H, F, Cl, Br, I, and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 F;

R_8 is selected from H and CH_3;

R_a is each independently selected from F, Cl, Br, I, OH, NH_2, CN, C_{1-3} alkyl, C_{1-3} alkoxy, C_{2-3} alkynyl and C_{2-3} alkenyl, wherein the C_{1-3} alkyl, C_{1-3} alkoxy, C_{2-3} alkynyl and C_{2-3} alkenyl are optionally substituted with 1, 2 or 3 F;

R_b is each independently selected from F, Cl, Br, I, OH and NH_2;

R_c is hexahydro-1H-pyrrolizinyl, wherein the hexahydro-1H-pyrrolizinyl is optionally substituted with 1, 2 or 3 R;





R_d is each independently selected from F, Cl, Br, I, OH, NH_2 and CN;



R is each independently selected from H, F, Cl, Br, OH, CN, C_{1-3} alkyl, C_{1-3} alkoxy and -C_{1-3} alkyl-O-C(=O)-C_{1-3} alkylamino;



provided that when R_1 is naphthyl, the naphthyl is optionally substituted with F, Cl, Br, OH, NH_2, CF_3, CH_2CH_3 and -C≡CH, and R_5, R_6 and R_7 are each independently H.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_a is each independently selected from F, Cl, Br, I, OH, NH_2, CN, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3, -CH=CH_2, -CH_2-CH=CH_2 and -C≡CH, wherein the CH_3, CH_2CH_3, OCH_3, OCH_2CH_3, -CH=CH_2, -CH_2-CH=CH_2 and -C≡CH are optionally substituted with 1, 2 or 3 F; alternatively, wherein R_a is each independently selected from F, OH, NH_2, CH_3, CF_3, CH_2CH_3 and -C≡CH.

3. The compound according to any one of claims 1-2, or a pharmaceutically acceptable salt thereof, wherein R_1 is selected from phenyl, naphthyl, indolyl and indazolyl, wherein the phenyl, naphthyl, indolyl and indazolyl are optionally substituted with 1, 2 or 3 R_a.



4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R_1 is selected from , , , and .



5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_c is selected from , and ;

alternatively, wherein R_c is selected from , and .

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein


R_3 is CH_3, wherein the CH_3 is optionally substituted with 1, 2 or 3 R_c.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein R_3 is selected from  and ;

alternatively, wherein R_3 is selected from  and .

8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_4 is selected from H and CH_3, wherein the CH_3 is optionally substituted with 1, 2 or 3 R_d; alternatively, wherein R_4 is selected from H, CH_3 and CH_2CN.

9. The compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by formula (P-1):



(P-1)

wherein

R_1 is as defined in any one of claims 1-4;

R_4 is C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_d;


R_d is each independently selected from F, Cl, Br, I, OH, NH_2 and CN;

R_5 is as defined in claim 1;

R_c is as defined in any one of claims 1 and 5;

the carbon atom with "*" is a chiral carbon atom, which exists in the form of (R) or (S) single enantiomer or is enriched in one enantiomer.

10. A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,



(III)

wherein

T_1 is selected from O and N;

R_1 is selected from phenyl, naphthyl and indazolyl, wherein the phenyl, naphthyl and indazolyl are optionally substituted with 1, 2, 3, 4 or 5 R_a;

when T_1 is O, R_2 is not present;

when T_1 is N, R_2 is selected from H, C_{1-3} alkyl, -C(=O)-C_{1-3} alkyl and -S(=O)$_2$-C_{1-3} alkyl, wherein the C_{1-3} alkyl, -C(=O)-C_{1-3} alkyl and -S(=O)$_2$-C_{1-3} alkyl are optionally substituted with 1, 2 or 3 R_b;

R_3 is C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_c;

R_4 is selected from H and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_d;

R_5, R_6 and R_7 are each independently selected from H, F, Cl, Br, I, OH and NH_2;

R_8 is selected from H and CH_3;

R_a is each independently selected from F, Cl, Br, I, OH, NH_2, CN, CH_3, CF_3 and OCH_3;





R_b is each independently selected from F, Cl, Br, I, OH and NH_2;

R_c is hexahydro-1H-pyrrolizinyl, wherein the hexahydro-1H-pyrrolizinyl is substituted with 1, 2 or 3 R;





R_d is each independently selected from F, Cl, Br, I, OH, NH_2 and CN; and

R is each independently selected from H, F, Cl, Br and CH_3.





11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof,

wherein R_1 is selected from , ,  and .

12. The compound according to claim 10, or a pharmaceutically acceptable salt thereof,


wherein R_c is selected from  and  ; alternatively, wherein R_c is selected from  and  .

13. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R_3 is CH_3, wherein the CH_3 is optionally substituted with 1, 2 or 3 R_c; alternatively,

wherein R_3 is selected from  and  ; alternatively, wherein R_3 is selected from  and  .

14. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R_4 is selected from H and CH_3, wherein the CH_3 is optionally substituted with 1, 2 or 3 R_d; alternatively, wherein R_4 is selected from H, CH_3 and CH_2CN.

15. The compound according to any one of claims 1-8 and 10-14, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by formula (IV-2):



(IV-2)


wherein

R_4 is as defined in any one of claims 1, 8, 10, and 14;

R_5, and R_8 are as defined in any one of claims 1 and 10;


R is as defined in any one of claims 1 or 10.



16. A compound represented by the following formula, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from













;

alternatively, wherein the compound is selected from






;


alternatively, wherein the compound is selected from











.

17. A compound, which is:




or



,

or a pharmaceutically acceptable salt thereof.

18. A compound, which is:



,

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition, comprising the compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof.